Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733873 | 0.84 | PTGS1 (0.53) | METTL3ALDH1A3APPPTGS1PTGS2 | |
| Bromide SCHEMBL28933613 | 0.82 | PTGS1 (0.51) | METTL3ALDH1A3APPPTGS1PTGS2 | |
| SCHEMBL3367812 | 0.80 | NPC1 (0.64) | METTL3ROCK2USP30NPSR1EGLN1 | |
| SCHEMBL2087968 | 0.80 | PTGS1 (0.51) | PTGS1PTGS2EGLN1CYP2C9NR4A2 | |
| SCHEMBL2085892 | 0.80 | RAB9A (0.50) | METTL3PTGS1PTGS2EGLN1 | |
| SCHEMBL21947017 | 0.80 | APP (0.51) | METTL3ALDH1A3APPPTGS1PTGS2 | |
| SCHEMBL1728496 | 0.78 | PTGS1 (0.50) | APPPTGS1PTGS2EGLN1CYP2C9 | |
| SCHEMBL2087802 | 0.78 | PTGS1 (0.46) | PTGS1PTGS2EGLN1CYP2C9NR4A2 | |
| SCHEMBL4211423 | 0.78 | RAB9A (0.53) | PTGS1PTGS2EGLN1CYP2C9NR4A2 | |
| SCHEMBL2086415 | 0.78 | RXFP1 (0.47) | METTL3APPPTGS1PTGS2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902219-B2 | 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-08 | — | — | US | claimed |
| EP-2040703-B1 | DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2009-10-21 | — | — | EP | claimed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | claimed |
| US-7902219-B2 | 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-08 | — | — | US | disclosed |
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143420-A1 | 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | NR4A2, NR4A3, NCOR1 | METTL3 2012/4885ALDH1A3 1218/4885APP 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.